WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

Givaudan SA GIVN

SIX SwissSpecialty chemicalsFinancials to Sep 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
GIVN financials
Moat score
87
ROIC
12.3%
P/E
39.3
EV/EBIT
33.3
FCF yield
3.0%
Dividend yield
1.8%
Market cap
CHF 37.5B

Moat ranks

Score rankTied #65 of 396
Durabilitydurable
Market structureOligopoly
Pricing powerstrong

Balance sheet

6/30/26
CHF BDec 31Jun 30
Cash0.70.3
Securities0.00.0
Debt4.04.5
Net cash-3.3-4.2
Equity4.54.4
Leverage
Debt / EBITDA
2.78×
Debt / equity
1.03×
Leases (6/30/26)
CHF 389M
Capital
Diluted shares
9M
Book value / share
CHF 473.48
Price / book
8.5×
Net cash / share
−CHF 453.37
Market cap
CHF 37.5B
Enterprise value
CHF 41.7B

Per-share record

Fiscal years and TTM
Scale
CHF 0CHF 250CHF 500CHF 750CHF 1,000'16'17'18'19'20'21'22'23'24805.51'25796.71TTM
Revenue per shareCash flow per share

Key indicators

Latest: H1 '26
IndicatorLatestVs year agoLast 8 halves
Revenue growth-1.7%-5.1 pts
Operating margin16.7%-3.0 pts
FCF margin-0.6%-2.5 pts
Capex / revenue5.5%+0.9 pts
Research and product development spendingCHF 286M+4%
Net working capital as a share of sales30.8%+3.7 pts
Taste & Wellbeing like-for-like sales growth+2%–
Fragrance & Beauty like-for-like sales growth+9%–
Fine Fragrance like-for-like sales growth+15%–

Margins and growth from reported quarters; company KPIs as reported in results releases.

About GIVN

Givaudan supplies customer-specific flavours, fragrances and related ingredients to food, beauty and consumer-product brands. In 2025, Fragrance & Beauty supplied 51.3% of sales and Taste & Wellbeing 48.7%.

Revenue mix
Fragrance & Beauty 51.3%Taste & Wellbeing 48.7%
  • Design In Qualification

    Customer wins are typically brief-driven and co-created; qualification and reformulation make supplier switching costly for branded food & beverage manufacturers.

  • Scope Economies

    Breadth across flavours, taste solutions, and adjacent functional/natural ingredients enables integrated solutions and cross-selling to the same customer R&D teams.

  • Capex Knowhow Scale

    Scaled innovation platform (creation and application centres, R&D spend, patents) supports faster product cycles and customer-specific solutions across categories.

  • Operational Excellence

    Givaudan manages a complex global sourcing and customer-application network.

Timeline
  1. Sep 29, 2026

    The CMA kept its fragrance investigation open with a December update planned; Givaudan continues to face legal uncertainty without an infringement finding.

  2. Sep 21, 2026

    Givaudan gained dual independent certification for its product carbon-footprint programme covering more than 90,000 products; standardised data helps customers meet procurement and reporting needs.

  3. Sep 16, 2026

    A US court gave final approval to IFF’s end-user fragrance settlement. It leaves the claims against Givaudan and other defendants in place, so a competitor’s settlement does not end Givaudan’s civil exposure.

  4. Jul 23, 2026

    Givaudan reported CHF 83m of H1 legal settlements and provisions, reducing profit and showing that customer relationships do not protect against regulatory and product-liability exposure.

  5. Jun 30, 2026 · Half year · Legal charge −CHF 83M

    Fragrance competition settlement and a provision for an adverse Missouri judgment on alleged lung injury from diacetyl and 2,3 pentanedione. The filing reports one combined amount, so the two cases cannot be split.

Financial record

Fiscal year2016201720182019202020212022202320242025TTMTrendChange 2016–25
Per share (CHF)
Revenue502.09543.94594.84667.93680.38719.42769.14747.06799.87805.51796.71+5.4%/yr
Cash flow86.6892.7298.58122.32127.96138.63102.45148.33175.36163.00155.75+7.3%/yr
Earnings69.3477.5471.3675.5979.9688.3792.5196.47117.63115.46102.61+5.8%/yr
Free cash flow67.7366.3466.9487.87103.53111.0869.60118.62143.74130.12119.39+7.5%/yr
Capex18.9526.3831.6434.4624.4327.5532.8529.7131.6232.8836.36+6.3%/yr
Dividends53.3055.4657.4759.4461.4563.4065.6066.6667.6669.5371.42+3.0%/yr
Book value354.57381.01399.29391.95375.60422.89457.36431.38494.03489.11473.48+3.6%/yr
Diluted shares (M)99999999999-0.0%/yr
Totals (CHF B)
Revenue4.75.15.56.26.36.77.16.97.47.57.4+5.4%/yr
Operating income0.90.90.90.91.01.11.11.11.41.41.3+5.2%/yr
Net income0.60.70.70.70.70.80.90.91.11.11.0+5.8%/yr
Free cash flow0.60.60.60.81.01.00.61.11.31.21.1+7.5%/yr
Buybacks0.10.00.00.10.10.10.10.00.00.0–-6.8%/yr
Dividends0.50.50.50.60.60.60.60.60.60.60.7+3.0%/yr
Net cash-0.9-1.1-2.8-3.2-3.6-4.0-4.1-3.9-3.6-3.3-4.2−CHF 2.3B
Margins & returns (%)
Gross margin45.644.542.140.842.142.738.841.244.143.543.7-2.1 pts
Operating margin18.817.216.014.815.816.315.616.118.818.516.9-0.3 pts
Net margin13.814.312.011.311.812.312.012.914.714.312.9+0.5 pts
FCF margin13.512.211.313.215.215.49.015.918.016.215.0+2.7 pts
ROIC17.516.011.411.311.911.611.312.014.515.012.3-2.6 pts
Return on equity19.620.417.919.321.320.920.222.423.823.621.7+4.0 pts
R&D % of revenue8.68.48.68.58.58.47.37.57.67.47.6-1.2 pts
Stock pay % of revenue0.70.70.70.70.91.00.10.40.80.70.9-0.0 pts
Capex % of revenue3.84.95.35.23.63.84.34.04.04.14.6+0.3 pts

Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.

TTM = two half years to Sep 30, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 15.3% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score87
Strength
Confidence
Structure
Oligopoly
Durability
durable
Trajectory
stable
Pricing power
strong
Segments
  • Taste & Wellbeing48.7%
    4 claims
  • Fragrance & Beauty51.3%
    3 claims

Moat claims

Applies to
Taste & Wellbeing
Confidence
Durability
durable
Trajectory
stableas of Oct 6, 2026
Why it holds

Customer wins are typically brief-driven and co-created; qualification and reformulation make supplier switching costly for branded food & beverage manufacturers.

Why stable

Taste & Wellbeing grew 0.5% like-for-like in H1 2026; price increases and customer-specific recipes still support retention, but weak demand limits growth.

Indicators
  • Taste & Wellbeing like-for-like sales growth+2%
Risks
  • Customer consolidation increases buyer power
  • Commoditisation of standard flavours
  • Large customers dual-source or insource flavour development

Profile change log

  1. Oct 6, 2026 · business change

    A US court gave final approval to IFF’s end-user fragrance settlement. It leaves the claims against Givaudan and other defendants in place, so a competitor’s settlement does not end Givaudan’s civil exposure.

  2. Oct 6, 2026 · analyst revision

    Taste & Wellbeing operating-excellence strength falls from 3 to 2 and its direction turns narrowing after the CSB findings. Fragrance IP is classified as proprietary-formula differentiation rather than an essential IP bottleneck. Each debate figure now links to a source that reports it.

  3. Oct 6, 2026 · business change

    The US Chemical Safety Board found critical reactive-hazard and safeguard failures at Givaudan’s Louisville plant after the explosion that killed two workers. The site permanently closed, weakening the claim of superior operating reliability.

  4. Oct 6, 2026 · analyst revision

    Supply-chain evidence supports operating reliability rather than exclusive control. The fragrance IP claim is weaker because patents and secret formulas do not establish an indispensable component. Revenue weights use FY2025 division sales rather than H1 2026. Both divisions now link to their shared markets, with trajectories and a testable investor debate.

  5. Oct 6, 2026 · business change

    The CMA kept its fragrance investigation open with a December update planned; Givaudan continues to face legal uncertainty without an infringement finding.

  6. Oct 6, 2026 · business change

    Givaudan reported CHF 83m of H1 legal settlements and provisions, reducing profit and showing that customer relationships do not protect against regulatory and product-liability exposure.

  7. Oct 6, 2026 · business change

    Givaudan agreed to acquire a majority stake in Eurofragance, expanding regional fragrance creation and customer reach; terms are undisclosed and regulatory closing remains pending.

  8. Oct 6, 2026 · business change

    Christian Stammkoetter became CEO after Gilles Andrier; his consumer-products experience adds customer insight while execution of the next growth cycle remains untested.

  9. Oct 6, 2026 · business change

    Givaudan gained dual independent certification for its product carbon-footprint programme covering more than 90,000 products; standardised data helps customers meet procurement and reporting needs.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianGIVN
No peer numbers yet

Peers appear on the map as their numbers are collected.

Global B2B fragrance and beauty ingredients

As of Oct 6, 2026
OligopolyMedium cyclicality

Fragrance compounds, proprietary scent molecules and active beauty ingredients sold to perfume, personal care and home care manufacturers. This is an ingredient and formulation market; retail perfume and cosmetics sales are excluded.

  1. Givaudan
  2. DSM-Firmenich
  3. IFF
  4. Symrise
2025 leaders, no comparable shares · Givaudan
StocksMoatGross m.Op. m.
GIVN8743.7%16.9%
Industry median117543.7%14.8%
Sector median147641.3%16.5%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Fine fragrance launches and growing interest in scent increase demand for new customer-specific creations.
  • Personal care and home care consumption provides repeat volume alongside the more discretionary fine fragrance business.
  • Online commerce and regional fragrance brands create new customer briefs and shorten product launch cycles.
  • Natural and biotechnology ingredients create reformulation opportunities and can reduce dependence on scarce natural inputs.
Risks
  • Consumer caution and customer destocking can reduce ingredient orders even when end-user consumption remains stable.
  • Energy, feedstock and natural ingredient costs can rise before contract prices reset; tariffs add sourcing and logistics costs.
  • A stronger reporting currency reduces translated sales and profit from global demand; company H1 2026 results show a material FX effect.
  • Ingredient restrictions require reformulation, while competition investigations and civil litigation create legal and customer-trust risks.
  • Higher interest rates raise the cost of carrying inventories and financing acquisitions for indebted suppliers; weaker consumer demand can extend the time between ingredient purchases and customer payment.

Bulls & bears

Key question · as of Nov 11, 2026

Can Givaudan turn its customer-specific creations and ingredient breadth into stronger growth and cash generation while absorbing legal costs, input inflation and the strong Swiss franc?

Arguments

3 forFaded: weakening or settled4 against

What to watch

  1. 1Taste & Wellbeing like-for-like sales
  2. 2Fine Fragrance and Consumer Products like-for-like sales versus DSM-Firmenich and other peers
  3. 3Gross research spending and new-product evidence
  4. 4Operating cash flow and net working capital
  5. 5Separate legal charges, competition investigation outcomes and process-safety improvements

Next check: December 2026 CMA update and 27 January 2027 full-year results for cash conversion and North American Taste & Wellbeing demand.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 9, 2026. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 87/100 by <a href="https://www.findmymoat.com/stocks/XSWX:GIVN">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.